$BCRX
Biocryst Pharmaceuticals Inc.
PRICE
$10.345 ▼-2.221%
Last Close
VOLUME
1,282,286
DAY RANGE
10.56 - 10.98
52 WEEK
7.61 - 19.99
Join Discuss about BCRX with like-minded investors
@lucullus #droscrew
institutions loading up on bios during this sell off. Big pharma facing a patent cliff. $MYOV black rock tripled holding size, Bellevue doubled to close to 12%. Biotech 2nd half is going to be buyout land, MYOV, BCRX, AUPH, CLVS anything with a drug that produce revenues
66 Replies 6 👍 10 🔥
@lucullus #droscrew
just goes to show you Flow can be a load of crap.... i sometimes wonder if folks dont put some flow in so they can sell there positions to folks.... $BCRX lead drug is worth around $30 a share so it is not a big deal ...one of their trial candidates has been stopped
62 Replies 11 👍 8 🔥
@lucullus #droscrew
nice recovery with that BCRX i bought today ... AUPH not so much
107 Replies 9 👍 15 🔥
Key Metrics
Market Cap
1.97 B
Beta
1.24
Avg. Volume
3.27 M
Shares Outstanding
186.42 M
Yield
0%
Public Float
0
Next Earnings Date
2023-02-23
Next Dividend Date
Company Information
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
CEO: Jon Stonehouse
Website: www.biocryst.com
HQ: 4505 Emperor Blvd Ste 200 Durham, 27703-8457 North Carolina
Related News